Evidence map›Paper›PMID 35937407›Full record

ArticleBioMed research international2022

Assessment of Bacterial Isolates from the Urine Specimens of Urinary Tract Infected Patient.

Chennu M M Prasada Rao, T Vennila, Sreya Kosanam, P Ponsudha, K Suriyakrishnaan, Abdullah A Alarfaj, Abdurahman Hajinur Hirad, S R Sundaram, P A Surendhar, Nagarajan Selvam

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Chennu M M Prasada RaoDepartment of Pharmaceutical Chemistry, School of Pharmacy, Raffles University, Neemrana, Rajasthan 301020, India.
T VennilaDepartment of Chemistry, Sri Sairam Engineering College, Chennai, Tamil Nadu 602109, India.
Sreya KosanamDepartment of Pharmacology and Pharmacy Practice, Nirmala College of Pharmacy, Atmakur, Andhra Pradesh 522503, India.
P PonsudhaDepartment of Electronics and Communication Engineering, Velammal Engineering College, Chennai, Tamil Nadu 600066, India.
K SuriyakrishnaanDepartment of Electronics and Communication Engineering, Sona College of Technology, Salem, Tamil Nadu 636005, India.
Abdullah A AlarfajDepartment of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Abdurahman Hajinur HiradDepartment of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
S R SundaramDepartment of Sciences, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
P A SurendharDepartment of Biomedical Engineering, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India.
Nagarajan SelvamDepartment of Computer Science, Ambo University, Ethiopia.ORCID https://orcid.org/0000-0002-7695-0104
King Saud University · SAAmbo University · ETNirma (India) · INRaffles UniversitySri Ramachandra Institute of Higher Education and Research · INUniversity of Tennessee Health Science Center · USVels University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary tract infections (UTIs) maintained a serious public health concern, as did the growth in antibiotic resistance both between uropathogenic microorganisms. A regular assessment of the microbiological agents that cause UTIs, as well as their antimicrobial resistance, is essential for a tailored empirical antibiotic response. Knowing the variables that cause UTIs can help you intervene quickly and simply to get the condition under control. The most common infecting species in acute infection is Escherichia coli (E. coli). To strengthen infection control strategies, it is necessary to know the prevalence and location of UTI. The goal of this research is to measure the frequency of microorganisms isolated from patients with UTIs as well as the antimicrobial sensitivity characteristics of Gram-negative bacteria. The purpose of this research has been to evaluate the frequency of UTIs by extracting and characterizing the various bacterial etiological organisms, as well as to assess the factors linked to UTIs. The goal of this research is to identify, characterize, and establish the antibiotic susceptibility patterns of bacteria linked to urinary tract infections. Fresh collected urine specimen was taken from inpatients or outpatients in UTI cases and bacteriologically tested using conventional microbiological methods. The Kirby-Bauer disc diffusion method was used to create the antibiogram. Staphylococcus saprophyticus, Staphylococcus aureus (28%), and Escherichia coli (24.6%) were the most common isolates (20%). The evaluated agents' antibacterial activity was all in the following order: cefixime, ciprofloxacin, augmentin, gentamicin, ceftazidime, nitrofurantoin, ofloxacin, and cefuroxime. It was discovered that each and every one of the microbes exhibited varied degrees of resistance to the antibiotics nitrofurantoin, ciprofloxacin, and ofloxacin. Every type of bacteria, with the exception of those belonging to the genus Streptococcus, has a Multiple Antibiotic Resistance Index (MARI) that is more than 0.2. The first-line therapies for urinary tract infections (UTIs) in the region would consist of ciprofloxacin, ofloxacin, and nitrofurantoin. Lower urinary tract infections almost never result in problems if they are diagnosed and treated as soon as possible and in the correct manner. However, if treatment is not sought, a urinary tract infection can lead to serious complications.

Indexed as

Escherichia coli InfectionsUrinary TractUrinary Tract InfectionsAnti-Bacterial AgentsCiprofloxacinDrug Resistance, BacterialEscherichia coliHumansMicrobial Sensitivity TestsNitrofurantoinOfloxacinAnti-Bacterial AgentsCiprofloxacinNitrofurantoinOfloxacin

Identifiers

PMID35937407
PMCPMC9348933
OpenAlexW4288067558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.